Sep 2026· Journal of Clinical Investigation· 0 citations
Medicine
TL;DR
Findings characterize TPH1's contribution to NEPC and suggest TPH1 as a potential therapeutic target and suggest TPH1 as a potential therapeutic target.
Abstract
Advanced prostate cancer has increasingly developed a lethal neuroendocrine form, small cell/neuroendocrine prostate cancer (NEPC), as a consequence of the widespread use of highly potent androgen receptor signaling inhibitors in castration-resistant disease. The molecular mechanisms remain unclear and no effective therapies currently exist. We report that tryptophan hydroxylase 1 (TPH1), the enzyme responsible for peripheral serotonin biosynthesis - a neurotransmitter enriched in neuroendocrine tumors and a classical neuroendocrine biomarker - was upregulated in both de novo and therapy-induced human NEPC. TPH1 upregulation was necessary and sufficient for neuroendocrine differentiation and the NEPC phenotype through its enzymatic activity. Silencing TPH1 suppressed neuroendocrine plasticity and various aggressive behaviors of NEPC cells, including proliferation, invasion, sphere formation, and NEPC tumor xenograft growth. Mechanistically, TPH1 activated mTOR via intracellular serotonin-dependent serotonylation of mTOR at glutamine 2453, which triggered the induction of FOXM1 and E2F1 to drive NEPC differentiation and growth. Importantly, pharmacological inhibition of TPH1 using the clinically available inhibitor LX1606 effectively restricted growth and neuroendocrine marker expression in multiple NEPC cell lines and patient-derived xenografts. Collectively, these findings characterize TPH1's contribution to NEPC and suggest TPH1 as a potential therapeutic target.
This study reveals the previously uncharacterized of ZNF281 in promoting androgen receptor–dependent transcription and androgen receptor-independent proliferative and metastatic programs in prostate cancer, advances understanding of disease progression across different androgen receptor expression statuses, and establi...
Guo-Cheng Huang, Maria Areli Lorenzana-Carrillo, Hua Chen et al.· bioRxiv· 0 citations
Abstract Background Enzalutamide resistance in advanced prostate cancer often leads to treatment‐induced neuroendocrine prostate cancer (t‐NEPC), characterized by aggressive lineage plasticity. The molecular regulators governing neuroendocrine differentiation and phenotypic transition are not well understood. Here, we...
Xiu-Chen Guo, Yi-Fan Liu, Jia-Cheng Huang et al.· Clinical and Translational M...· 0 citations
Prostate cancer (PCa) is a biologically diverse malignancy with a clinical trajectory that often culminates in treatment resistance and aggressive phenotypes. Among these, neuroendocrine prostate cancer (NEPC) represents a particularly lethal variant that arises either de novo or through transdifferentiation from conve...
B. Nezami, Xiao-Qi Lin· Seminars in diagnostic patho...· 0 citations
Docetaxel is a major therapeutic option for advanced prostate cancer, but the development of acquired resistance substantially limits its clinical efficacy. Although multiple mechanisms have been implicated in docetaxel resistance, the upstream regulatory pathways coordinating these phenotypes remain incompletely under...
Duygu Duzgun, W. Read, S. Oltean· bioRxiv· 0 citations
Lactate uptake through monocarboxylate transporter 1 (MCT1) is associated with aggressive disease in non-small cell lung cancer (NSCLC), but how lactate transport supports tumor metabolism remains incompletely understood. Integrating stable isotope tracing, metabolomics, and transcriptomics across patient tumors, anima...
Robert B. Cameron, Kristen E. Shema, Nathan Dubois et al.· bioRxiv· 0 citations
Cancer remains one of the leading causes of mortality worldwide and represents a multifactorial disease characterized by the dysregulation of multiple interconnected biological processes, including uncontrolled cell proliferation, resistance to apoptosis, metabolic reprogramming, angiogenesis, chronic inflammation, imm...
Alexia Barbarossa, A. Carrieri, E. Macchia et al.· Mini-Reviews in Medical Chem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.